Literature DB >> 14982738

Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs?

Bruce J Brew1, Louise Pemberton, John Ray.   

Abstract

Resistance to antiretroviral drugs in human immunodeficiency virus (HIV) disease may be discordant between blood and cerebrospinal fluid (CSF). However, there is no method by which patients who are likely to harbor resistant HIV in the CSF can be noninvasively identified. Activated monocytes are known to traffic through the brain and perivascular microglia are considered to "turnover" regularly from bone marrow-derived monocytes. Monocytes lack certain kinases necessary to metabolize some antiretroviral drugs, making it possible that monocytes, could deliver antiretroviral drugs to the brain. Low monocyte counts in the peripheral blood, however, would be expected to lead to decreased trafficking and turnover of monocytes, with less drug delivery to the brain. The authors hypothesized that this would increase the likelihood of drug resistant HIV in the central nervous system. To test this, 24 matching CSF and plasma samples that had been prospectively collected and stored from patients treated with nucleoside analogue reverse transcriptase inhibitor drugs were assessed for genotypic resistance. Those CSFs, with evidence of resistance mutations, were compared to those without for peripheral blood monocyte count, hemoglobin, CD4 cell count, and zidovudine (ZDV) use. The same analyses were repeated on the plasma samples. There were 11 CSFs with evidence of resistance mutations. The peripheral blood monocyte count was significantly lower in the CSF resistant group (0.29 +/- 0.16) versus (0.52 +/- 0.21) x 10(9)/L (P <.001). There was no difference between the groups according to hemoglobin, CD4 cell count, total white cell count, or use of ZDV. There was no difference between resistant and sensitive plasma samples according to peripheral blood monocyte count. To further test the hypothesis, the authors determined the concentrations of ZDV, stavudine, and abacavir in monocytes after each drug had been added to monocyte cultures. There was a significant decline in the concentration of each drug in the supernatant, implying that it had been "taken up" by the monocytes. These preliminary data suggest that peripheral blood monocytes may be important in delivery of antiretroviral drugs to the brain and the development of resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982738     DOI: 10.1080/753312751

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  19 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.

Authors:  P H Cunningham; D G Smith; C Satchell; D A Cooper; B Brew
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

3.  Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.

Authors:  W A O'Brien; A Namazi; H Kalhor; S H Mao; J A Zack; I S Chen
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

4.  Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Authors:  P G Hoggard; S Kewn; M G Barry; S H Khoo; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir.

Authors:  E R Lanier; G Sturge; D McClernon; S Brown; M Halman; N Sacktor; J McArthur; J H Atkinson; D Clifford; R W Price; D Simpson; G Torres; J Catalan; K Marder; C Power; C Hall; C Romero; B Brew
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

6.  Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.

Authors:  G Venturi; M Catucci; L Romano; P Corsi; F Leoncini; P E Valensin; M Zazzi
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

7.  Kynurenine pathway inhibition reduces neurotoxicity of HIV-1-infected macrophages.

Authors:  S J Kerr; P J Armati; L A Pemberton; G Smythe; B Tattam; B J Brew
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

Review 8.  Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.

Authors:  Stefano Aquaro; Raffaele Caliò; Jan Balzarini; Maria Concetta Bellocchi; Enrico Garaci; Carlo Federico Perno
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

9.  Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2.

Authors:  W E Aulitzky; H Tilg; W Vogel; W Aulitzky; M Berger; G Gastl; M Herold; C Huber
Journal:  Ann Hematol       Date:  1991-02       Impact factor: 3.673

10.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more
  3 in total

Review 1.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

2.  Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment.

Authors:  Karl Goodkin; Benedetto Vitiello; William D Lyman; Deshratn Asthana; J Hampton Atkinson; Peter N R Heseltine; Rebeca Molina; Wenli Zheng; Imad Khamis; Frances L Wilkie; Paul Shapshak
Journal:  J Neurovirol       Date:  2006-06       Impact factor: 2.643

3.  Sex-based differences in neurocognitive functioning in HIV-infected young adults.

Authors:  Ruxandra Burlacu; Anya Umlauf; Anca Luca; Sara Gianella; Roxana Radoi; Simona M Ruta; Thomas D Marcotte; Luminita Ene; Cristian L Achim
Journal:  AIDS       Date:  2018-01-14       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.